Single Enzyme Essential for APC-Deficient Cancer Cell Survival

APC-deficient cancer cells rely on single enzyme for survival A newly published study reveals that colorectal cancer cells lacking the APC tumor suppressor protein depend on a single metabolic enzyme, ALDH2, for survival. This discovery identifies a potential therapeutic strategy to selectively target one of the most common genetic alterations in colorectal cancer while sparing healthy cells. The APC gene is mutated in over 60% of colorectal cancers, making it one of the most frequent drivers of the disease. However, directly targeting APC has remained challenging due to its role as a tumor suppressor. Instead, researchers have focused on identifying synthetic lethal interactions—where inhibiting a second gene becomes deadly only in the context of APC loss. Using bioinformatics screening followed by experimental validation, scientists found that ALDH2, an enzyme involved in cellular detoxification, is critically required for the viability of APC-deficient colorectal cancer cells. When ALDH2 is inhibited—using compounds like disulfiram—these cells experience a significant reduction in proliferation and increased cell death. The mechanism involves the accumulation of reactive oxygen species (ROS) following ALDH2 inhibition. This oxidative stress disrupts cellular homeostasis and activates the ASK1/JNK signaling pathway, which regulates apoptosis. Pro-apoptotic factors like BAX increase while anti-apoptotic factors like Bcl2 decrease, triggering programmed cell death specifically in APC-deficient cells. Importantly, cells with functional APC show minimal sensitivity to ALDH2 inhibition, highlighting a selective vulnerability that could be exploited therapeutically. In preclinical models, disulfiram treatment significantly inhibited tumor growth and increased apoptosis in APC-mutant colorectal cancer xenografts. These findings suggest that ALDH2 inhibition represents a promising precision medicine approach for treating APC-driven colorectal cancers. By exploiting this metabolic dependency, future therapies may offer a way to target tumors that have long been considered “undruggable” due to the nature of the APC mutation. As research progresses, clinical trials evaluating ALDH2 inhibitors—either alone or in combination with existing treatments—will be needed to determine their efficacy and safety in patients with APC-mutant colorectal cancer. This strategy exemplifies how understanding cancer-specific vulnerabilities can lead to more effective and less toxic treatment options.